Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry
Here we introduce an Accelerator Mass Spectrometry (AMS)-based high precision method for quantifying the number of cancer cells that initiate metastatic tumors, in xenograft mice. Quantification of 14 C per cell prior to injection into animals, and quantification of 14 C in whole organs allows us to...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2018-10, Vol.8 (1), p.15013-10, Article 15013 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Here we introduce an Accelerator Mass Spectrometry (AMS)-based high precision method for quantifying the number of cancer cells that initiate metastatic tumors, in xenograft mice. Quantification of
14
C per cell prior to injection into animals, and quantification of
14
C in whole organs allows us to extrapolate the number of cancer cells available to initiate metastatic tumors. The
14
C labeling was optimized such that 1 cancer cell was detected among 1 million normal cells. We show that ~1–5% of human cancer cells injected into immunodeficient mice form subcutaneous tumors, and even fewer cells initiate metastatic tumors. Comparisons of metastatic site colonization between a highly metastatic (PC3) and a non-metastatic (LnCap) cell line showed that PC3 cells colonize target tissues in greater quantities at 2 weeks post-delivery, and by 12 weeks post-delivery no
14
C was detected in LnCap xenografts, suggesting that all metastatic cells were cleared. The
14
C-signal correlated with the presence and the severity of metastatic tumors. AMS measurements of
14
C-labeled cells provides a highly-sensitive, quantitative assay to experimentally evaluate metastasis and colonization of target tissues in xenograft mouse models. This approach can potentially be used to evaluate tumor aggressiveness and assist in making informed decisions regarding treatment. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-018-33368-0 |